Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma [PDF]
openalex +1 more source
Mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience [PDF]
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021. However, there is a lack of real-life studies.
Barbieri, Maria Antonietta+18 more
core +1 more source
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience [PDF]
Gilda Varricchi+5 more
openalex +1 more source
Mepolizumab For The Treatment of Chronic Asthma. A Meta-Analysis of Randomized Placebo-Controlled Trials [PDF]
Raju Kanukula, N Likhar, Amit Dang
openalex +1 more source
S4 Implications of guidance in scotland on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis [PDF]
CEA Hartmann+4 more
openalex +1 more source
Care pathways for the selection of a biologic in severe asthma [PDF]
Bousquet, Jean+12 more
core +2 more sources
P14 Therapeutic benefit of mepolizumab in the national institute of health and care excellence (nice) sub-population– a post-hoc meta-analysis of phase iib/iii trials [PDF]
H Marwaha+4 more
openalex +1 more source
Characteristics of Asthmatic Responders to Mepolizumab after Failed Response to Omalizumab [PDF]
Geetika Sabharwal, Faoud T. Ishmael
openalex +1 more source
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma [PDF]
Frank C. Albers+7 more
openalex +1 more source